60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Debt-to-EBITDA : -0.02 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

60 Degrees Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. 60 Degrees Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.15 Mil. 60 Degrees Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2023 was $-8.07 Mil. 60 Degrees Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for 60 Degrees Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

SXTPW' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -46.68 Med: -14.58 Max: -0.12
Current: -0.12

During the past 4 years, the highest Debt-to-EBITDA Ratio of 60 Degrees Pharmaceuticals was -0.12. The lowest was -46.68. And the median was -14.58.

SXTPW's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs SXTPW: -0.12

60 Degrees Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Debt-to-EBITDA Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-46.68

-18.53

-10.63

-0.12

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial						-10.32	-4.20	-2.94	0.01	-0.02

Competitive Comparison of 60 Degrees Pharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Debt-to-EBITDA falls into.

60 Degrees Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

60 Degrees Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.022	+	0.15)	/	-1.427
	=	-0.12

60 Degrees Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.022	+	0.15)	/	-8.068
	=	-0.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

60 Degrees Pharmaceuticals (NAS:SXTPW) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

60 Degrees Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

SXTP:USA

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.